黑料网

ISSN: 2476-2253

Journal of Cancer Diagnosis
黑料网

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • J Cancer Diagn,

Revolutionizing Cancer Diagnosis: The Promise of Liquid Biopsy

Subhrajyoti Sharma*
Department of Healthcare Science and Technology, Institute of RKS Engineering Science and Technology, India
*Corresponding Author : Subhrajyoti Sharma, Department of Healthcare Science and Technology, Institute of RKS Engineering Science and Technology, India, Email: Subhrajyoti_sh@gmail.com

Received Date: May 01, 2024 / Accepted Date: May 30, 2024 / Published Date: May 30, 2024

Abstract

Liquid biopsy has emerged as a promising non-invasive diagnostic approach for various diseases, particularly cancer. Unlike traditional tissue biopsies, which involve invasive procedures, liquid biopsy involves the analysis of biomarkers, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and circulating tumor DNA (ctDNA), present in bodily fluids like blood, urine, and saliva. This technique offers several advantages, including real-time monitoring of disease progression, assessment of treatment response, and early detection of relapse. Liquid biopsy holds immense potential for personalized medicine by enabling clinicians to tailor treatment strategies based on the molecular profile of individual patients. Moreover, it facilitates the study of tumor heterogeneity and evolution, aiding in the development of targeted therapies and the identification of drug resistance mechanisms. However, challenges such as standardization of protocols, sensitivity and specificity issues, and cost-effectiveness need to be addressed for widespread clinical adoption. This review provides an overview of liquid biopsy technologies, their applications across different disease contexts, current challenges, and future perspectives.

Liquid biopsy has emerged as a promising non-invasive diagnostic tool revolutionizing the field of medicine, particularly in oncology. This innovative approach involves the analysis of various biomarkers, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and circulating RNA, obtained from biofluids like blood, urine, or cerebrospinal fluid. The ability to detect and analyze tumor-derived material from peripheral blood offers significant advantages over traditional tissue biopsies, including real-time monitoring of disease progression, early detection of cancer, assessment of treatment response, and identification of resistance mechanisms. This review comprehensively explores the principles, methodologies, clinical applications, challenges, and future perspectives of liquid biopsy in oncology, emphasizing its potential to personalize cancer management and improve patient outcomes.

Citation: Subhrajyoti S (2024) Revolutionizing Cancer Diagnosis: The Promise of Liquid Biopsy. J Cancer Diagn 8: 241.

Copyright: © 2024 Subhrajyoti S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top